Treating moderate to severe psoriasis - Best use of biologicsCitation formats

Standard

Treating moderate to severe psoriasis - Best use of biologics. / Lynch, Maeve; Kirby, Brian; Warren, Richard B.

In: Expert review of clinical immunology, Vol. 10, No. 2, 02.2014, p. 269-279.

Research output: Contribution to journalArticlepeer-review

Harvard

Lynch, M, Kirby, B & Warren, RB 2014, 'Treating moderate to severe psoriasis - Best use of biologics', Expert review of clinical immunology, vol. 10, no. 2, pp. 269-279. https://doi.org/10.1586/1744666X.2014.873701

APA

Lynch, M., Kirby, B., & Warren, R. B. (2014). Treating moderate to severe psoriasis - Best use of biologics. Expert review of clinical immunology, 10(2), 269-279. https://doi.org/10.1586/1744666X.2014.873701

Vancouver

Lynch M, Kirby B, Warren RB. Treating moderate to severe psoriasis - Best use of biologics. Expert review of clinical immunology. 2014 Feb;10(2):269-279. https://doi.org/10.1586/1744666X.2014.873701

Author

Lynch, Maeve ; Kirby, Brian ; Warren, Richard B. / Treating moderate to severe psoriasis - Best use of biologics. In: Expert review of clinical immunology. 2014 ; Vol. 10, No. 2. pp. 269-279.

Bibtex

@article{4313862e576e4cb5b65df9f9e4d780ff,
title = "Treating moderate to severe psoriasis - Best use of biologics",
abstract = "This review focuses on the efficacy, safety and best use of biologic agents in moderate-to-severe psoriasis. Recommendations from two recent guidelines are summarised. The NICE Guidelines 2012 provide recommendations on best practice for prescribing biologics. The German S3 Guidelines are based on a systematic review of published studies and report the efficacy of biologics and guidelines for treatment. Data on the safety of biologics are available for up to 5 years in psoriasis and are on the whole reassuring. Registry data is evolving and will provide data on safety to help inform long-term monitoring of patients with psoriasis on biologics agents. New anti-interleukin-17 (IL17) and anti-IL17RA biologics are in Phase 3 clinical trials and may prove to be more effective than existing biologics. {\textcopyright} 2014 Informa UK Ltd.",
keywords = "biologics, efficacy, psoriasis, registries, safety",
author = "Maeve Lynch and Brian Kirby and Warren, {Richard B.}",
year = "2014",
month = feb,
doi = "10.1586/1744666X.2014.873701",
language = "English",
volume = "10",
pages = "269--279",
journal = "Expert review of clinical immunology",
issn = "1744-8409",
publisher = "Expert Reviews Ltd",
number = "2",

}

RIS

TY - JOUR

T1 - Treating moderate to severe psoriasis - Best use of biologics

AU - Lynch, Maeve

AU - Kirby, Brian

AU - Warren, Richard B.

PY - 2014/2

Y1 - 2014/2

N2 - This review focuses on the efficacy, safety and best use of biologic agents in moderate-to-severe psoriasis. Recommendations from two recent guidelines are summarised. The NICE Guidelines 2012 provide recommendations on best practice for prescribing biologics. The German S3 Guidelines are based on a systematic review of published studies and report the efficacy of biologics and guidelines for treatment. Data on the safety of biologics are available for up to 5 years in psoriasis and are on the whole reassuring. Registry data is evolving and will provide data on safety to help inform long-term monitoring of patients with psoriasis on biologics agents. New anti-interleukin-17 (IL17) and anti-IL17RA biologics are in Phase 3 clinical trials and may prove to be more effective than existing biologics. © 2014 Informa UK Ltd.

AB - This review focuses on the efficacy, safety and best use of biologic agents in moderate-to-severe psoriasis. Recommendations from two recent guidelines are summarised. The NICE Guidelines 2012 provide recommendations on best practice for prescribing biologics. The German S3 Guidelines are based on a systematic review of published studies and report the efficacy of biologics and guidelines for treatment. Data on the safety of biologics are available for up to 5 years in psoriasis and are on the whole reassuring. Registry data is evolving and will provide data on safety to help inform long-term monitoring of patients with psoriasis on biologics agents. New anti-interleukin-17 (IL17) and anti-IL17RA biologics are in Phase 3 clinical trials and may prove to be more effective than existing biologics. © 2014 Informa UK Ltd.

KW - biologics

KW - efficacy

KW - psoriasis

KW - registries

KW - safety

U2 - 10.1586/1744666X.2014.873701

DO - 10.1586/1744666X.2014.873701

M3 - Article

C2 - 24372444

VL - 10

SP - 269

EP - 279

JO - Expert review of clinical immunology

JF - Expert review of clinical immunology

SN - 1744-8409

IS - 2

ER -